While R55 partially rescues retromer association in vitro, its therapeutic potential in animal models or clinical settings remains unknown. This translational gap is critical for determining whether retromer stabilization represents a viable treatment strategy for Parkinson's disease. Gap type: open_question Source paper: Parkinson Disease-linked Vps35 R524W Mutation Impairs the Endosomal Association of Retromer and Induces α-Synuclein Aggregation. (2016, The Journal of biological chemistry, PMID:27385586)
Landscape Summary: Can retromer-stabilizing compounds like R55 prevent neurodegeneration in vivo? is a 0.87 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: investigating.
Colonna, Sevlever, et al. (TREM2 biology)
Can retromer-stabilizing compounds like R55 prevent neurodegeneration in vivo? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: